New drug combination versus standard therapy for acute monocytic leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether a newer drug called venetoclax, combined with a chemotherapy regimen called CACAG, works better than the standard "3+7" chemotherapy for treating acute monocytic leukemia (a blood cancer). The goal is to help patients achieve remission and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 60 years old
- You have been diagnosed with acute monocytic leukemia (not acute promyelocytic leukemia)
- Your liver and kidney function are near-normal (specific blood test levels)
- You do not have an active, uncontrolled infection
- You are willing to follow all study visits and procedures
- You have not had major surgery in the past 6 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of venetoclax plus a chemotherapy regimen (called CACAG) against a standard chemotherapy regimen (3+7) for adults with newly diagnosed intermediate- or high-risk AML. The goal is to see if the new combination works better.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
This trial tests a combination of four drugs (venetoclax, azacitidine, chidamide, and CAG chemotherapy) to treat newly diagnosed acute myeloid leukemia (AML—a blood cancer) in adults aged 60–75. The goal is to see if this combination helps patients live longer and feel better.
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
This trial tests a new combination therapy called VAG for people with acute myeloid leukemia (AML) who haven't been treated before. The goal is to see if it works better than standard treatments.
Hear when a new Acute Monocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.